Czarnecka-Czapczyńska, MagdalenaBartusik-Aebisher, DorotaKrupka-Olek, MagdalenaAebisher, DavidCieślar, GrzegorzLatos, WojciechKawczyk-Krupka, Aleksandra2021-11-022021-11-022021European Journal of Clinical and Experimental Medicine T. 19, z. 3 (2021), s. 241–2452544-2406http://repozytorium.ur.edu.pl/handle/item/6852Introduction. Coronavirus disease 2019 (COVID-19) was first observed in China in Wuhan city, Hubei province in December, 2019, and specified as a pandemic by the World Health Organization (WHO). COVID-19 is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV2). Aim. The aim of this article is to discuss epidemiology of thromboembolic complication in COVID-19. Material and methods. This article is a review done in regards to discuss clinical features of the anticoagulation treatment in COVID-19. Analysis of the literature. A review is discussed an anticoagulation treatment in 41 manuscripts. Conclusion. Most commonly coagulation abnormalities in patient with COVID-19 is mild thrombocytopenia. Apart from their typical role in thrombosis and hemostasis, platelets mediate key aspects of immune and inflammatory.engAttribution-NonCommercial-NoDerivatives 4.0 Międzynarodowehttp://creativecommons.org/licenses/by-nc-nd/4.0/anticoagulationcoagulation abnormalitiesCOVID-19review10.15584/ejcem.2021.3.52544-1361